278P - The impact of progesterone receptor on node-negative breast cancer survival

Date 01 October 2012
Event ESMO Congress 2012
Session Poster presentation III
Topics Breast Cancer, Early Stage
Presenter mustafa Solak
Authors M. Solak1, F. Paksoy2, O. Keskin3, N. Kertmen3, M.K. Altundag3
  • 1Medical Oncology, Hacettepe University Oncology Institutte, Ankara/TR
  • 2Medical Oncology, Ankara Onkoloji Hastanesi, 006 - Ankara/TR
  • 3Medical Oncology, Hacettepe University Oncology Institutte, 06 - 100/TR



The aim of this study was to evaluate tumor characteristics and survival rates of node-negative breast cancer patients according to progesterone receptor (PR) status.


Of 2,218 breast cancer cases diagnosed between 1995 and 2011 in Hacettepe University, Institute of Oncology; 864 node-negative patients with known hormone receptor status were analyzed for age, tumor size, grade, lymphovascular invasion and HER-2/neu status. Estrogen receptor (ER), PR and HER-2 status were determined using immunohistochemistry. Patients were classified into four groups; ER + /PR + , ER + /PR-, ER-/PR+ and ER-/PR-. Pearson Chi-Square test and Kaplan-Meier with log-rank test were performed for statistical analysis.


575 (66.6%) patients had ER + PR + , 64 (7.4%) had ER + PR-, 43 (5.0%) had ER-PR+ and 182 (21.1%) had ER-PR- tumor. The median age of patients were 48 years (20-83) and were similar in all groups (p = 0.18). Majority of patients with PR- tumors were postmenopausal at the time of diagnosis (p = 0.021). The follow-up period was 39.5 (1-273) months.


Patients in PR- groups are more likely to have large-size and HER-2 positive breast cancer. ER- groups are associated with high grade disease. Patients with PR+ breast cancer have significantly longer overall survival, compared to patients with ER+ tumors. Our data suggest that PR status is an important prognostic factor for node-negative breast cancer survival.


All authors have declared no conflicts of interest.